These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28363206)

  • 1. Recent developments in the science of proarrhythmic cardiac safety of new drugs.
    Turner JR; Karnad DR; Cabell CH; Kothari S
    Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):118-124. PubMed ID: 28363206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy.
    Turner JR; Rodriguez I; Mantovani E; Gintant G; Kowey PR; Klotzbaugh RJ; Prasad K; Sager PT; Stockbridge N; Strnadova C;
    J Clin Pharmacol; 2018 Aug; 58(8):997-1012. PubMed ID: 29672845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced long QT syndrome: Concept and non-clinical models for predicting the onset of drug-induced torsade de pointes in patients in compliance with ICH E14/S7B guidance.
    Sugiyama A; Goto A; Izumi-Nakaseko H; Takei Y; Takahara A; Kambayashi R
    J Pharmacol Exp Ther; 2024 Aug; ():. PubMed ID: 39168651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
    Fermini B; Hancox JC; Abi-Gerges N; Bridgland-Taylor M; Chaudhary KW; Colatsky T; Correll K; Crumb W; Damiano B; Erdemli G; Gintant G; Imredy J; Koerner J; Kramer J; Levesque P; Li Z; Lindqvist A; Obejero-Paz CA; Rampe D; Sawada K; Strauss DG; Vandenberg JI
    J Biomol Screen; 2016 Jan; 21(1):1-11. PubMed ID: 26170255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
    Vicente J; Stockbridge N; Strauss DG
    J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early drug development: assessment of proarrhythmic risk and cardiovascular safety.
    Lester RM; Olbertz J
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1611-1618. PubMed ID: 27718759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
    Cavero I; Holzgrefe H
    Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
    Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
    J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs, QT interval prolongation and ICH E14: the need to get it right.
    Shah RR
    Drug Saf; 2005; 28(2):115-25. PubMed ID: 15691222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
    Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
    J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action Potential Morphology Accurately Predicts Proarrhythmic Risk for Drugs With Potential to Prolong Cardiac Repolarization.
    Lee W; Ng B; Mangala MM; Perry MD; Subbiah RN; Vandenberg JI; Hill AP
    Circ Arrhythm Electrophysiol; 2023 Jul; 16(7):399-410. PubMed ID: 37334695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
    Shah RR
    Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiographic biomarkers to confirm drug's electrophysiological effects used for proarrhythmic risk prediction under CiPA.
    Vicente J; Hosseini M; Johannesen L; Strauss DG
    J Electrocardiol; 2017; 50(6):808-813. PubMed ID: 28928044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
    Pugsley MK; Curtis MJ; Hayes ES
    Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thorough QT (TQT) studies: concordance with torsadogenesis and an evolving cardiac safety testing paradigm.
    Wiśniowska B; Tylutki Z; Polak S
    Drug Discov Today; 2017 Oct; 22(10):1460-1465. PubMed ID: 28511997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.